Penningtons Manches has advised King’s College London on an investment from Takeda Pharmaceutical and Abingworth into GammaDelta Therapeutics.
GammaDelta was established in 2016 from work undertaken by Professor Adrian Hayday and Oliver Nussbaumer at King’s and the Francis Crick Institute. The investment, which will provide up to $100 million towards further research and development, also includes an option for Takeda to purchase GammaDelta in the future.
GammaDelta has developed a T-cell platform based on the properties of gamma delta T cells in human tissues. The investment is intended to be used by the company to develop new immunotherapies which could treat a wide range of cancers and autoinflammatory diseases.
The Penningtons Manches team comprised specialists from the firm’s corporate and intellectual property practices, and included partner Chris Shelley.